TGTX Insider Trading
Insider Ownership Percentage: 10.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $781,496.86
TG Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at TG Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
TG Therapeutics Share Price & Price History
Current Price: $43.86
Price Change: ▲ Price Increase of +1.83 (4.35%)
As of 04/29/2025 05:00 PM ET
TG Therapeutics Insider Trading History
TG Therapeutics Institutional Trading History
Data available starting January 2016
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Read More on TG Therapeutics
Today's Range
Now: $43.86
52 Week Range
Now: $43.86
Volume
2,692,394 shs
Average Volume
3,079,370 shs
Market Capitalization
$6.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.14
Who are the company insiders with the largest holdings of TG Therapeutics?
Who are the major institutional investors of TG Therapeutics?
Which institutional investors are selling TG Therapeutics stock?
In the previous quarter, TGTX stock was sold by these institutional investors:
- Assenagon Asset Management S.A.
- Bank of New York Mellon Corp
- Illinois Municipal Retirement Fund
- Teacher Retirement System of Texas
- Wealth Effects LLC
- Hennion & Walsh Asset Management Inc.
- State of Alaska Department of Revenue
- Rhumbline Advisers
In the previous year, company insiders that have sold TG Therapeutics company stock include:
- Michael S Weiss (CEO)
- Sean A Power (CFO)
Learn More investors selling TG Therapeutics stock.
Which institutional investors are buying TG Therapeutics stock?
In the last quarter, TGTX stock was bought by institutional investors including:
- GAMMA Investing LLC
- New York State Teachers Retirement System
- Braun Stacey Associates Inc.
- Spire Wealth Management
- Principal Financial Group Inc.
- Allspring Global Investments Holdings LLC
- Grimes & Company Inc.
- Canton Hathaway LLC